Clinical trial NCT04398628: ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Official title: ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hematologic Disorder
Bleeding Disorder
Connective Tissue Disorder
Hemophilia
Thrombosis
Von Willebrand Diseases
Thrombophilia
Rare Bleeding Disorder
Platelet Disorder
Factor IX Deficiency
Factor VIII Deficiency
Thalassemia
Sickle Cell Disease
Lead sponsor: American Thrombosis and Hemostasis Network
Sponsor class: NETWORK
Collaborators: name: Pfizer
name: Hemophilia of Georgia, Inc.
name: Genentech, Inc.
name: Hemab Therapeutics
name: CSL Behring
name: Sanofi
name: Novo Nordisk A/S
First posted: 2020-05-21
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This is a real-world study in which participants with congenital or acquired blood disorders will be enrolled.

Brief summary: In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well-controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.(1,2,3,4) In 2019 alone, the United States Food and Drug Administration (FDA) has issued approvals for twenty-four new therapies for congenital and acquired hematologic conditions.(5) In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.(6) With this increase in potential new therapies on the horizon, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data.

ATHN Transcends is a cohort study to determine the safety, effectiveness, and practice of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. The study consists of 7 cohorts with additional study "arms" and "modules" branching off from the cohorts.

The overarching objective of this longitudinal, observational study is to characterize the safety, effectiveness and practice of treatments for all people with congenital and acquired hematologic disorders in the US.

As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.(7)

Detailed description: This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at the time of enrollment, quarterly, annually, and ad hoc. Base data will be collected for all participants. Specific data will be collected for participants enrolled in cohort-specific Arms and Modules.

Each participant will be assigned to a single cohort: Hemophilia, Von Willebrand Disease, Congenital Platelet Disorders, Rare Disorders, Bleeding Not Otherwise Specified (NOS), Thrombosis/Thrombophilia, or Non-Neoplastic Hematologic Conditions.

Study Arms and study Modules may be developed to provision disease and/or disease specific insights related to stakeholders, including but not limited to pharmaceutical companies, ATHN, and Hemophilia Treatment Centers (HTCs). Arms may branch off into product-specific data collection via Modules to be collected during the study, in conjunction with planned study assessments.

ATHN Transcends Principal Investigators

Tammuella Chrisentery-Singleton, MD Ochsner Clinic Foundation American Thrombosis and Hemostasis Network

Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation

PUPs Arm:

Principal Investigator:

Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital

ALTUVIIO Module:

Co-Principal Investigators Shannon Carpenter, MD, MS University of Missouri Kansas City School of Medicine Children's Mercy Hospital

Co-Principal Investigator Julie Jaffray, MD University of California San Diego Rady Children's Hospital San Diego

INHIBIT Module:

Co-Principal Investigators:

Nicoletta Machin DO, MS Assistant Professor, Division of Hematology/Oncology Hemophilia Center of Western Pennsylvania University of Pittsburgh Medical Center

Hemophilia Natural History Arm:

Co-Principal Investigators:

Tyler Buckner, MD, MSc Hemophilia and Thrombosis Center University of Colorado Anschutz Medical Campus

Michael Recht, MD, PhD, MBA Yale University School of Medicine National Bleeding Disorders Foundation

Rebinyn Module

Co-Principal Investigators:

Lauren Amos, MD Children's Mercy Hospital, Kansas City

Guy Young, MD University of Southern California Children's Hospital Los Angeles

Hemophilia Gene Therapy Outcomes Arm:

Co-Principal Investigators:

Janice M. Staber, MD Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Children's Hospital

Ulrike M. Reiss, MD Hemophilia Treatment Center St. Jude's Children's Research Hospital

Severe VWD Natural History Arm:

Co-Principal Investigators:

Robert F. Sidonio, Jr., MD, MSc Aflac Cancer and Blood Disorders Center, Hemophilia of Georgia Center for Bleeding and Clotting Disorders

Angela C. Weyand, MD C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor

Congenital Platelet Disorders Natural History Arm:

Principal Investigator Sanjay Ahuja, MD Rainbow Babies \& Children's Hospital, Case Western Reserve University

Glanzmann Thrombasthenia Module:

Co-Principal Investigators:

Divya Citla-Sridhar, MD University of Arkansas for Medical Sciences Arkansas Children's Hospital

Meera Chitlur, MD Children's Hospital of Michigan

Hemophilia Cohort

This cohort includes three Arms and five Modules:

Previously Untreated Patients (PUPs) Arm This is a pediatric focused Arm of PUPs with hemophilia A or B.

ALTUVIIIO® Module The purpose is to investigate the safety and effectiveness of ALTUVIIIO® in PUPs with hemophilia A.

INHIBIT Module This is an observational study assessing inhibitor formation in children with severe hemophilia A.

Hemophilia Natural History Arm This Arm is investigating the safety, effectiveness, and practice of treatment for people with hemophilia.

Hemlibra® Module All participants treated with Hemlibra® are eligible to participate.

Rebinyn® Module The Rebinyn® Module is a prospective study in hemophilia B participants without inhibitors.

Hemophilia Gene Therapy Outcomes Arm This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia.

HEMGENIX® Module This is an observational study to characterize the effectiveness and safety of HEMGENIX® in participants with hemophilia B.

Congenital Platelet Disorders (CPD) Natural History Arm:

The CPD Arm is investigating the safety and efficacy of hemostatic therapies in the prevention or treatment of bleeding events in adult and pediatric participants with inherited congenital platelet disorders.

Glanzmann Thrombasthenia (GT) Module:

This Module is a study of bleeding symptoms, treatments, and treatment outcomes in patients with Glanzmann thrombasthenia.

Von Willebrand Disease Cohort No arms or modules open at this time.

Rare Disorders Cohort No arms or modules open at this time.

Bleeding NOS No arms or modules open at this time.

Thrombosis/Thrombophilia No arms or modules open at this time.

Non-Neoplastic Hematologic Conditions No arms or modules open at this time.

Eligibility criteria: Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in the base study:

Inclusion Criteria:

1. Any age
2. Having a congenital or acquired non-neoplastic hematologic disorder; or
3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or
4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score.

Exclusion Criteria:

1. Does not qualify for inclusion in a cohort 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures

Cohort Participant Selection

Each participant is to be enrolled in the cohort for which they qualify as defined below.

Hemophilia Cohort

Inclusion Criteria:

Participants who meet any of the following inclusion criteria are eligible for enrollment into this cohort:

1. Factor VIII or factor IX activity \< 50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR
2. Being a known carrier for congenital hemophilia with a factor VIII or factor IX activity greater than or equal to 50% with or without a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score; OR
3. Known congenital hemophilia that have a factor level \>50% after receiving vector; OR
4. Acquired hemophilia

Exclusion Criteria:

None

Von Willebrand Disease Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Meeting the definition of VWD or low VWF per most recent international guidelines

Exclusion Criteria:

None

Congenital Platelet Disorders Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Abnormalities of platelet function

   1. Glanzmann thrombasthenia (GPIIb or GPIIIa)
   2. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX)
2. Abnormalities of platelet granules
3. Abnormalities of platelet signal transduction
4. Abnormalities of platelet secretion
5. Collagen Receptor Defect
6. ADP Receptor Defect
7. Thromboxane Receptor Defect
8. Giant Platelet Disorder
9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related)

Exclusion Criteria:

Platelet disorders secondary to medications or other substances

Rare Disorders Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following:

1. PAI-1 deficiency
2. Factor I, II, V, VII, X, XI, XIII deficiencies
3. Combined FV and FVIII deficiency
4. Plasminogen deficiency
5. Decreased tissue plasminogen activator
6. Afibrinogenemia/hypofibrinogenemia/dysfibrinogenemia

Exclusion Criteria:

None

Bleeding NOS Cohort

Inclusion Criteria:

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Have a bleeding phenotype as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; OR
2. Connective tissue disorder with bleeding tendency as indicated by an age-adjusted abnormal ISTH Bleeding Assessment Tool score

Exclusion Criteria:

None

Thrombosis/Thrombophilia Cohort

Inclusion Criteria

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Have a prior history of arterial or venous thrombosis
2. Patients with a known congenital or acquired thrombophilia with or without a thrombosis a. Common congenital thrombophilias:: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies/Beta2 glycoprotein antibodies iii. Antiphospholipid syndrome

Exclusion Criteria

1. Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy, overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity/bedrest, heart failure, inflammatory bowel disease, or kidney disease

Non-Neoplastic Hematologic Conditions Cohort

Inclusion Criteria

Participants who meet the following inclusion criteria are eligible for enrollment into this cohort:

1. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort

Exclusion Criteria

None

Previously Untreated Patients Arm Eligibility Criteria

Inclusion Criteria Diagnosis of congenital hemophilia A (FVIII \<40%) or hemophilia B (FIX \<40% or below lower limit for age)

1. Age \<18 years at time of enrollment
2. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent
3. Care established at one of the participating HTCs

Exclusion Criteria

1. CFC exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets \>3 EDs
2. Concomitant diagnosis with another bleeding disorder
3. History of confirmed inhibitor

INHIBIT Module Eligibility Criteria:

Inclusion Criteria

1. Diagnosis of severe factor VIII deficiency with baseline factor VIII level \<1%
2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement
3. Factor exposure, plasma/FFP, cryo, and single donor platelets ≤3 EDs
4. ≤5 years of age

Exclusion Criteria

1. Concomitant diagnosis with bleeding disorder other than hemophilia A
2. Immune disorder
3. Factor exposure, plasma/FFP, cryo, and single donor platelets \>3 EDs
4. Previous history or presence of factor VIII inhibitor

ALTUVIIIO® Module Eligibility Criteria:

Inclusion criteria:

* People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists \<5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of \<1%)
* \<18 years of age
* No history of FVIII inhibitor
* Sex at birth of male, female, or intersex
* Participants may be exposed to unfractionated blood components, no more than one dose of FVIII concentrate other than efanesoctocog alfa and up to three doses of efanesoctocog alfa prior to enrollment
* Potential participants who have a history of bleeding will be eligible for participation if they meet all other inclusion criteria

Exclusion criteria:

* Not meeting all the inclusion criteria
* Any exposure to blood components or FVIII replacement products except as described in the inclusion criteria
* History of positive inhibitor testing
* History of hypersensitivity reactions associated with efanesoctocog alfa administration
* Any concurrent clinically significant major disease that, in the investigator's opinion, would make the participant unsuitable for enrollment.
* The presence of any additional inherited bleeding disorder diagnosis
* Enrollment in a concurrent clinical interventional drug study
* Intake of an Investigational Medicinal Product within three months prior to inclusion in this study
* Inability to comply with study requirements
* Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment.

Hemophilia Natural History Arm Eligibility Criteria:

Inclusion Criteria

1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility.

Exclusion Criteria

1. Presence of any known bleeding disorder other than congenital hemophilia A or B
2. Presence of concurrent hemophilia and a second hemostatic defect (low Von Willebrand Factor (VWF) without VWD diagnosis is not excluded)
3. Unable or unwilling to comply with the study arm protocol.

Rebinyn® Module Eligibility Criteria

Inclusion Criteria:

Participants who meet the following inclusion criteria at the time of screening are eligible to enroll in the study module.

Rebinyn® Cohort

1. Has provided signed written consent for the Rebinyn® Module before any study-related activities.
2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment.
3. Decision to initiate treatment with commercially available nonacog beta pegol has been made by the participant(s)/Legally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study.

Rebinyn® RWE Cohort

1. Has provided signed written consent for ATHN Transcends Study before any study-related activities.
2. Currently treated with nonacog beta pegol
3. Any age

Exclusion Criteria:

Participants who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study module:

Rebinyn® Cohort

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator.
3. Known or suspected hypersensitivity to nonacog beta pegol or related products.
4. Clinical suspicion or presence of FIX inhibitor at time of inclusion.
5. Inability or unwillingness to undergo the neurological assessment/ structured developmental history.

Rebinyn® RWE Cohort 1. None

Hemophilia Gene Therapy Outcomes Arm Eligibility Criteria:

Inclusion Criteria

1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months.
2. Age 18 years and older
3. Able to give informed consent.

   Exclusion Criteria None

   HEMGENIX® Module Eligibility Criteria

   Inclusion Criteria:

   HEMGENIX Cohort • Age 18 years of age or older

   • Treatment with commercial HEMGENIX

   • Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the treating site.

   Exclusion Criteria, both cohorts:

   • Have been treated with etranacogene dezaparvovec in a clinical trial.

   Congenital Platelet Disorders Arm Eligibility Criteria:

   Inclusion Criteria

<!-- -->

1. Platelet adhesion defect

   1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to VWF)
   2. Velocardio-facial syndrome/DiGeorge syndrome (Defective GPIb-IX-V receptor)
   3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between VWF-GP1bα)
2. Platelet aggregation defect

   1. Glanzmann thrombasthenia (Defective integrin αIIbβ3 (GPIIb/IIIa)
   2. Platelet aggregation defect, NOS
3. Agonist receptor defects

   1. Epinephrine
   2. ADP
   3. Collagen
   4. Thromboxane A2
4. Platelet signaling defects

   1. Cyclooxygenase deficiency (PTGS1 mutation)
   2. Phospholipase A2 deficiency
   3. Thromboxane synthase deficiency (TBXAS1 mutation)
   4. G protein activation defect (GNAS mutation)
   5. Scott syndrome (defect in phosphatidyl serine translocation)
5. Platelet Granule disorders

   1. Dense granule storage pool disorder • Hermansky Pudlak syndrome

      * Chediak Higashi syndrome
      * Griscelli syndrome
   2. Alpha granule storage pool disorder

      • Grey platelet syndrome
      * Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome
      * Quebec platelet disorder
      * Paris-Trousseau syndrome
   3. Combined alpha delta granule deficiency
6. Platelet cytoskeletal structure defects

   1. Wiskott Aldrich syndrome
   2. MYH9 associated disorders (myosin heavy chain)

      • May Hegglin syndrome

      • Fechtner syndrome
      * Sebastian syndrome
      * Epstein syndrome
   3. Other mutations • FLNA mutations (Filamin) • DIAPH1 (Actin and microtubules) • ACTN1 (alpha actinin) • TPM4 (tropomyosin)

      * TUBB1 (beta tubulin)
7. Other Congenital thrombocytopenias

   1. Familial platelet disorders and predisposition to AML (RUNX1)
   2. X linked thrombocytopenia with dyserythropoiesis (GATA1)
   3. Congenital amegakaryocytic thrombocytopenia (MPL)

Exclusion Criteria

1. Diagnosis of von Willebrand disease (Meeting the definition of VWD or low VWF per most recent international guidelines)
2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX ≤ 40%)

   FIX Prophylaxis Cohort

   • Age 18 years of age or older

   • Treatment with FIX prophylaxis therapy

   • Has provided signed written consent at any time for ATHN Transcends Study

   Glanzmann Thrombasthenia (GT) Module Eligibility Criteria:

   Inclusion Criteria

1. Participant has signed the informed consent/assent form 2. Participant has flow cytometry or aggregometry or genetics confirmed GT 3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months

Exclusion Criteria None

Primary outcomes:
measure: To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency.
timeFrame: 15 years
measure: To describe the safety and tolerability of efanesoctocog alfa in previously untreated patients (PUPs) with hemophilia A without a history of inhibitors.
timeFrame: 7 years
Secondary outcomes:
measure: To establish a platform to support study Arms and Modules for participants with bleeding, clotting, other non-neoplastic blood disorders, and connective tissue disorders with bleeding tendency.
timeFrame: 15 years
measure: To describe medication dosing regimens in the above conditions.
timeFrame: 15 years
measure: To grow and evolve a biorepository for current and future research through the collection of biospecimens from every person enrolled on this protocol.
timeFrame: 15 years
measure: To describe real-world effectiveness of therapies by evaluating for Health care utilization
timeFrame: 15 years
measure: To describe bleeding events, changes in overall bleeding, and annualized bleeding rate (ABR) as measured by individual bleeding components.
timeFrame: 15 years
Other outcomes:
measure: To describe real-world effectiveness of therapies by evaluating for Goal attainment
timeFrame: 15 years
measure: To describe real-world effectiveness of therapies by evaluating for Patient Reported Outcomes (PROs)
timeFrame: 15 years
measure: To describe real-world effectiveness of therapies by evaluating treatment adherence
timeFrame: 15 years
measure: To describe real-world effectiveness of therapies by evaluating health utility
timeFrame: 15 years
Locations:
city: Phoenix
country: United States
facility: Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital
state: Arizona
city: Little Rock
country: United States
facility: Arkansas Center for Bleeding Disorders
state: Arkansas
city: Los Angeles
country: United States
facility: Orthopaedic Institute for Children HTC
state: California
city: Los Angeles
country: United States
facility: Childrens Hospital Los Angeles
state: California
city: Oakland
country: United States
facility: UCSF Benioff Children's Hospital Oakland
state: California
city: Sacramento
country: United States
facility: University of California at Davis Hemophilia Treatment Center
state: California
city: San Bernardino
country: United States
facility: Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program
state: California
city: San Diego
country: United States
facility: Hemophilia & Thrombosis Treatment Center at UC San Diego Health
state: California
city: San Diego
country: United States
facility: Rady Children's Hospital San Diego
state: California
city: San Francisco
country: United States
facility: University of California, San Francisco Hemophilia & Thrombosis Center
state: California
city: Aurora
country: United States
facility: University of Colorado Denver Hemophilia and Thrombosis Center
state: Colorado
city: Hartford
country: United States
facility: Connecticut Children's Medical Center
state: Connecticut
city: New Haven
country: United States
facility: Yale Hemophilia Treatment Center
state: Connecticut
city: Wilmington
country: United States
facility: Delaware Hemophilia Treatment Center
state: Delaware
city: Washington
country: United States
facility: Georgetown University
state: District of Columbia
city: Washington
country: United States
facility: Children's National Hemophilia Center
state: District of Columbia
city: Gainesville
country: United States
facility: University of Florida Hemophilia Treatment Center
state: Florida
city: Miami
country: United States
facility: University of Miami Comprehensive Hemophilia Treatment Center
state: Florida
city: Orlando
country: United States
facility: Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders
state: Florida
city: Saint Petersburg
country: United States
facility: Johns Hopkins All Children's Hospital
state: Florida
city: Tampa
country: United States
facility: St. Joseph's Hospital Center for Bleeding & Clotting Disorders
state: Florida
city: Atlanta
country: United States
facility: Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta
state: Georgia
city: Atlanta
country: United States
facility: Emory/Children's Health Care of Atlanta
state: Georgia
city: Savannah
country: United States
facility: Memorial Health University Medical Center
state: Georgia
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Peoria
country: United States
facility: Bleeding and Clotting Disorders Institute
state: Illinois
city: Indianapolis
country: United States
facility: Indiana Hemophilia and Thrombosis Center
state: Indiana
city: Iowa City
country: United States
facility: Iowa Hemophilia and Thrombosis Center
state: Iowa
city: New Orleans
country: United States
facility: Louisiana Center for Bleeding and Clotting Disorders, Tulane University
state: Louisiana
city: Scarborough
country: United States
facility: Maine Hemophilia and Thrombosis Center
state: Maine
city: Baltimore
country: United States
facility: Johns Hopkins University Hemophilia Treatment Center
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center
state: Massachusetts
city: Detroit
country: United States
facility: Central Michigan Children's Hospital of Michigan
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Health System Bleeding and Thrombosis Treatment Center
state: Michigan
city: Rochester
country: United States
facility: Mayo Comprehensive Hemophilia Center
state: Minnesota
city: Kansas City
country: United States
facility: Children's Mercy Hospital - Kansas City
state: Missouri
city: Saint Louis
country: United States
facility: The John Bouhasin Center for Children with Bleeding Disorders
state: Missouri
city: Las Vegas
country: United States
facility: Cure 4 The Kids Foundation
state: Nevada
city: Reno
country: United States
facility: Hemostasis and Thrombosis Center of Nevada
state: Nevada
city: Newark
country: United States
facility: Newark Beth Israel Medical Center - Hemophilia Center
state: New Jersey
city: Albuquerque
country: United States
facility: University of New Mexico Ted R. Montoya Hemophilia & Thrombosis Program
state: New Mexico
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: Buffalo
country: United States
facility: Western New York BloodCare
state: New York
city: Hyde Park
country: United States
facility: Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College - New York Presbyterian Hospital
state: New York
city: Rochester
country: United States
facility: American Thrombosis and Hemostasis Network
state: New York
city: Chapel Hill
country: United States
facility: Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill
state: North Carolina
city: Charlotte
country: United States
facility: St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital
state: North Carolina
city: Greenville
country: United States
facility: East Carolina University Hemophilia Treatment Center
state: North Carolina
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences
state: North Carolina
city: Akron
country: United States
facility: Akron Children's Hospital - Showers Center for Cancer & Blood Disorders
state: Ohio
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center
state: Ohio
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center Hemophilia Treatment Center
state: Ohio
city: Cleveland
country: United States
facility: University Hospitals Health System Cleveland
state: Ohio
city: Columbus
country: United States
facility: Nationwide Children's Hospital Columbus
state: Ohio
city: Dayton
country: United States
facility: Dayton Children's Hemostasis and Thrombosis Center
state: Ohio
city: Toledo
country: United States
facility: Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital
state: Ohio
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
city: Philadelphia
country: United States
facility: Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Hemophilia Center of Western Pennsylvania
state: Pennsylvania
city: Providence
country: United States
facility: Rhode Island Hospital Hemostasis and Thrombosis Center
state: Rhode Island
city: Memphis
country: United States
facility: St. Jude Children's Research Hospital
state: Tennessee
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Austin
country: United States
facility: Children's Blood and Cancer Center of Central Texas
state: Texas
city: Dallas
country: United States
facility: North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders
state: Texas
city: Dallas
country: United States
facility: North Texas Comprehensive Hemophilia Treatment Center
state: Texas
city: Fort Worth
country: United States
facility: Fort Worth Bleeding Disorders Program
state: Texas
city: Houston
country: United States
facility: Gulf States Hemophilia and Thrombophilia Center
state: Texas
city: Houston
country: United States
facility: Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine
state: Texas
city: San Antonio
country: United States
facility: South Texas Comprehensive Hemophilia and Thrombophilia Treatment Center
state: Texas
city: Seattle
country: United States
facility: Washington Center for Bleeding Disorders
state: Washington
city: Green Bay
country: United States
facility: Hemophilia Outreach Center Green Bay
state: Wisconsin
city: Milwaukee
country: United States
facility: Comprehensive Center for Bleeding Disorders
state: Wisconsin
Study officials:
affiliation: Yale University School of Medicine & National Bleeding Disorders Foundation
name: Michael Recht, MD, PhD, MBA
role: PRINCIPAL_INVESTIGATOR
affiliation: ATHN, Ochsner Clinic Foundation
name: Tammuella Chrisentery-Singleton, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Weijer C, Freedman B, Fuks A, Robbins J, Shapiro S, Skrutkowska M. What difference does it make to be treated in a clinical trial? A pilot study. Clin Invest Med. 1996 Jun;19(3):179-83.
citation: Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol. 2001 Mar;54(3):217-24. doi: 10.1016/s0895-4356(00)00305-x.
citation: West J, Wright J, Tuffnell D, Jankowicz D, West R. Do clinical trials improve quality of care? A comparison of clinical processes and outcomes in patients in a clinical trial and similar patients outside a trial where both groups are managed according to a strict protocol. Qual Saf Health Care. 2005 Jun;14(3):175-8. doi: 10.1136/qshc.2004.011478.
citation: Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13.
citation: https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Accessed 04 Jul 2019
citation: https://www.clinicaltrials.gov/ct2/results?cond=Hematologic+Diseases&term=&cntry=&state=&city=&dist=. Accessed 04 Jul 2019
citation: Konkle BA, Recht M; members of Working Group 2, the NHLBI State of the Science Workshop on factor VIII inhibitors: Generating a national blueprint for future research. The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia. 2019 Jul;25(4):590-594. doi: 10.1111/hae.13772.
citation: Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 2016 Dec 15;5(4):e239. doi: 10.2196/resprot.6558.